α1-adrenoceptor antagonists, also known as α-blockers, are widely used in men with certain types of lower urinary tract symptoms (LUTS), although use of such agents alone often fails to address the symptoms of nocturia. The findings of a newly published randomized controlled study reveal that the addition of desmopressin to α-blocker monotherapy in men 40–65 years of age with LUTS and persistent nocturia is safe and effective. Significant improvements in the mean number of nocturia episodes and nocturnal urine volume, relative to those of men with similar symptoms who received α-blocker monotherapy, were observed.